Kancera AB (publ) - Asset Resilience Ratio

Latest as of March 2025: 65.98%

Kancera AB (publ) (KAN) has an Asset Resilience Ratio of 65.98% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Kancera AB (publ) carry for a breakdown of total debt and financial obligations.

Liquid Assets

Skr37.34 Million
≈ $4.02 Million USD Cash + Short-term Investments

Total Assets

Skr56.60 Million
≈ $6.09 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Kancera AB (publ)'s Asset Resilience Ratio has changed over time. See KAN net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Kancera AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kancera AB (publ) (KAN) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr37.34 Million 65.98%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr37.34 Million 65.98%

Asset Resilience Insights

  • Very High Liquidity: Kancera AB (publ) maintains exceptional liquid asset reserves at 65.98% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kancera AB (publ) Industry Peers by Asset Resilience Ratio

Compare Kancera AB (publ)'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Kancera AB (publ) (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Kancera AB (publ).

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 69.29% Skr46.36 Million
≈ $4.99 Million
Skr66.91 Million
≈ $7.20 Million
-0.32pp
2023-12-31 69.61% Skr45.69 Million
≈ $4.92 Million
Skr65.64 Million
≈ $7.06 Million
-9.20pp
2022-12-31 78.81% Skr95.15 Million
≈ $10.24 Million
Skr120.74 Million
≈ $12.99 Million
-1.04pp
2021-12-31 79.85% Skr106.52 Million
≈ $11.46 Million
Skr133.41 Million
≈ $14.36 Million
+13.65pp
2020-12-31 66.19% Skr55.01 Million
≈ $5.92 Million
Skr83.10 Million
≈ $8.94 Million
+39.48pp
2019-12-31 26.71% Skr11.85 Million
≈ $1.28 Million
Skr44.35 Million
≈ $4.77 Million
-19.46pp
2018-12-31 46.17% Skr21.02 Million
≈ $2.26 Million
Skr45.53 Million
≈ $4.90 Million
-8.05pp
2017-12-31 54.22% Skr27.77 Million
≈ $2.99 Million
Skr51.23 Million
≈ $5.51 Million
-24.87pp
2016-12-31 79.09% Skr57.76 Million
≈ $6.22 Million
Skr73.03 Million
≈ $7.86 Million
+78.92pp
2011-12-31 0.17% Skr67.00K
≈ $7.21K
Skr39.74 Million
≈ $4.28 Million
--
pp = percentage points

About Kancera AB (publ)

ST:KAN Sweden Biotechnology
Market Cap
$1.98 Million
Skr18.44 Million SEK
Market Cap Rank
#29694 Global
#693 in Sweden
Share Price
Skr0.15
Change (1 day)
-23.82%
52-Week Range
Skr0.15 - Skr2.00
All Time High
Skr38.15
About

Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the … Read more